DOD grant accelerates SARS-CoV-2 vaccine manufacturing

By The Science Advisory Board staff writers

March 24, 2020 -- The U.S. Department of Defense (DOD) has awarded Ology Bioservices and Inovio Pharmaceuticals an $11.9 million contract to rapidly manufacture DNA vaccines, the companies announced on March 24. Ology, a biologics contract development and manufacturing organization, will work with Inovio's DNA technology platform.

The grant is supported by the Office of the Assistant Secretary of Defense for Health Affairs with funding from the Defense Health Agency. It will enable the companies to work with Inovio's DNA vaccine (INO-4800) for protection against SARS-CoV-2 infection. The goal of the program is to rapidly and efficiently deliver the vaccine to the Department of Defense for upcoming clinical trials.

The combination of Ology's manufacturing resources and expertise and Inovio's promising vaccine candidate will enable the companies to offer a vaccine to protect the U.S. military and the entire nation against current and future disease outbreaks, according to the companies.

Frontera supercomputer aids COVID-19 drug development
Scientists are urgently working to build the first complete all-atom model of the SARS-CoV-2 coronavirus envelope, estimated to contain over 200 million...
Supercomputer reveals potential compounds against coronavirus
Researchers from the U.S. Department of Energy's Oak Ridge National Laboratory have used the Summit supercomputer to identify 77 small-molecule drug compounds...
New NIH study pinpoints how coronavirus attacks cells
The continued spread of the novel 2019 coronavirus, known as SARS-CoV-2, around the world has raised the need for a test to rapidly and efficiently screen...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter